Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:Local therapy in the context of MBCChoice of therapy after progression on available standards of careChoice of trastuzumab deruxtecan and tucatinib based on patient presentationManaging patients with CNS metastasesManaging interstitial lung diseasePresenters:Thomas Bachelot, MD, PhDChair, Unicancer Breast Group - UCBGBreast Cancer UnitMedical Oncology Centre Léon BérardLyon, FranceAdam M. Brufsky, MD, PhDProfessor of Medicine Hematology/Oncology University of Pittsburgh School of MedicineAssociate Chief, Hematology-OncologyUniversity of Pittsburgh Cancer InstitutePittsburgh, PennsylvaniaCristina Saura, MD, PhDMedicine and Surgery/Medical OncologyUniversidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)Head, Breast Cancer ProgramMedical OncologyVall d’Hebron University HospitalBarcelona, SpainContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including associated downloadable slidesets:https://bit.ly/32A1HMb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.